NZ Immuno-Oncology Research Review Issue 31

In this issue:
  -  Disparities in immunotherapy use for triple-negative breast cancer
  -  Efficacy and safety of ICIs in elderly patients with advanced NSCLC
  -  OS better in NSCLC when immunochemotherapy is administered in the morning
  -  Nivolumab-ipilimumab in microsatellite-instability-high metastatic colorectal cancer
  -  Burden and clinical trajectory of ICI-induced endocrinopathies
  -  First-line chemotherapy ± ICI for advanced gastric cancer
  -  Nervous system events associated with blinatumomab
  -  Induced pluripotent stem-cell-derived CD19-directed CAR NK cells for B-cell lymphoma
  -  10-year outcomes for nivolumab-ipilimumab in advanced melanoma
  -  Talquetamab-teclistamab for relapsed/refractory multiple myeloma

Please login below to download this issue (PDF)

Subscribe